| MSI and EBV positive gastric cancer’s subgroups and their link with novel immunotherapy MG Rodriquenz, G Roviello, A D’Angelo, D Lavacchi, F Roviello, K Polom Journal of clinical medicine 9 (5), 1427, 2020 | 72 | 2020 |
| Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives D Lavacchi, F Mazzoni, G Giaccone Drug design, development and therapy, 3187-3198, 2019 | 50 | 2019 |
| Immune checkpoint inhibitors in the treatment of renal cancer: current state and future perspective D Lavacchi, E Pellegrini, VE Palmieri, L Doni, MM Mela, F Di Maida, ... International journal of molecular sciences 21 (13), 4691, 2020 | 49 | 2020 |
| Tumor-agnostic treatment for cancer: when how is better than where D Lavacchi, G Roviello, A D’Angelo Clinical drug investigation 40, 519-527, 2020 | 43 | 2020 |
| Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer G Roviello, A D'Angelo, R Petrioli, F Roviello, F Cianchi, S Nobili, E Mini, ... Translational Oncology 13 (9), 100795, 2020 | 38 | 2020 |
| Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data M Rimini, L Fornaro, S Lonardi, M Niger, D Lavacchi, T Pressiani, ... Liver International 43 (8), 1803-1812, 2023 | 28 | 2023 |
| Results of the observational prospective RealFLOT study E Giommoni, D Lavacchi, G Tirino, L Fornaro, F Iachetta, C Pozzo, ... BMC cancer 21, 1-11, 2021 | 28 | 2021 |
| Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: a real-world analysis A Paderi, E Gambale, C Botteri, R Giorgione, D Lavacchi, M Brugia, ... Molecules 26 (19), 5789, 2021 | 27 | 2021 |
| Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer G Roviello, FU Conter, E Mini, D Generali, M Traversini, D Lavacchi, ... Cancer chemotherapy and pharmacology 84, 669-677, 2019 | 21 | 2019 |
| Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study M Bersanelli, S Buti, D Giannarelli, A Leonetti, A Cortellini, GL Russo, ... Lung Cancer 150, 123-131, 2020 | 16 | 2020 |
| Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer G Randon, R Intini, C Cremolini, E Elez, MJ Overman, J Lee, P Manca, ... European Journal of Cancer 161, 90-98, 2022 | 15 | 2022 |
| Electronic nicotine delivery systems (ENDS): not still ready to put on END D Lavacchi, G Roviello, MG Rodriquenz Journal of thoracic disease 12 (7), 3857, 2020 | 13 | 2020 |
| Perioperative tailored treatments for gastric cancer: times are changing D Lavacchi, S Fancelli, E Buttitta, G Vannini, A Guidolin, C Winchler, ... International Journal of Molecular Sciences 24 (5), 4877, 2023 | 12 | 2023 |
| Vinorelbine in non-small cell lung cancer: real-world data from a single-institution experience S Nobili, D Lavacchi, G Perrone, G Vicini, R Tassi, I Landini, AM Grosso, ... Oncology Research 28 (3), 237, 2020 | 12 | 2020 |
| Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer D Lavacchi, S Fancelli, G Roviello, F Castiglione, E Caliman, G Rossi, ... Frontiers in oncology 12, 1055019, 2022 | 11 | 2022 |
| Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) D Ciardiello, C Chiarazzo, V Famiglietti, A Damato, C Pinto, MG Zampino, ... ESMO open 7 (5), 100567, 2022 | 11 | 2022 |
| Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge D Lavacchi, I Landini, G Perrone, G Roviello, E Mini, S Nobili Pharmacology & Therapeutics 229, 107924, 2022 | 11 | 2022 |
| Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study F Nappo, L Fornaro, L Pompella, S Catanese, D Lavacchi, A Spallanzani, ... Journal of Cancer Research and Clinical Oncology 149 (9), 6601-6611, 2023 | 10 | 2023 |
| Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy E Caliman, S Fancelli, C Ottanelli, F Mazzoni, L Paglialunga, D Lavacchi, ... Cancer Treatment and Research Communications 32, 100603, 2022 | 10 | 2022 |
| Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience C Bardasi, A Spallanzani, S Benatti, F Spada, A Laffi, L Antonuzzo, ... Endocrine 74, 707-713, 2021 | 10 | 2021 |
Giandomenico Roviellouniversity of florence在 unifi.it 的电子邮件经过验证
